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Background: Treatment guidelines for major depressive disorder (MDD) are based on results from randomized
clinical trials, among others in psychotherapy efficacy trials. However, patients in these trials differ from routine
practice patients since trials use stringent criteria for patient selection. It is unknown whether the exclusion criteria
used in psychotherapy efficacy trials (PETs) influence symptom outcome in clinical practice. We first explored which
exclusion criteria are used in PETs. Second, we investigated the influence of commonly used exclusion criteria on
symptom outcome in routine clinical practice.
Methods: We performed an extensive literature search in PubMed, PsycInfo and additional databases for PETs for
MDD. From these, we identified commonly used exclusion criteria. We investigated the influence of exclusion
criteria on symptom outcome by multivariate regression models in a sample of patients suffering from MDD
according to the MINIplus from a routine clinical practice setting (n=598). Data on routine clinical practice patients
were gathered through Routine Outcome Monitoring.
Results: We selected 20 PETs and identified the following commonly used exclusion criteria: ‘a baseline severity
threshold of HAM-D≤14’, ‘current or past abuse or dependence of alcohol and/or drugs’ and ‘previous use of
medication or ECT’. In our routine clinical practice sample of patients suffering from MDD (n=598), presence of
‘current or past abuse of or dependence on alcohol and/or drugs’ had no significant influence on
outcome.‘Meeting a baseline severity threshold of HAM-D≤14’ and ‘previous use of medication or ECT’ were
associated with better outcome, but the explained variance of the models was very small (R2=2-11%).
Conclusions: The most consistently used exclusion criteria are not a major threat to the generalizability of results
found in PETs. However, PETs do somewhat improve their results by exclusion of patients with minor depression
and patients who used antidepressants prior to psychotherapy.
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In the development of guidelines, randomised con-
trolled trials (RCTs) and meta-analyses thereof are
considered the most reliable source of evidence. How-
ever, it is unknown to what extent the results of
these RCTs are generalizable to routine clinical prac-
tice. In RCTs, much effort is put in optimising the
internal validity, i.e. the possibility to determine to
what extent the observed efficacy is reproducible and
attributable to the investigated treatment. The internal
validity of trials is improved by the use of strict cri-
teria for patient selection. While this is very import-
ant for methodological and ethical reasons, it has
been demonstrated that the use of eligibility criteria
may well hamper the generalizability (external valid-
ity) of the results [1-6]. In trials of antidepressant
treatment of major depression (MDD), a fairly con-
sistent set of exclusion criteria is used [2]. Based on
this set of criteria, we and others found that only
12-34% of the patients who received treatment for
MDD in routine outpatient psychiatric care settings
and fee-for-service private practice were eligible for
participation in an antidepressant efficacy trial (AET)
[1,3] [7]. Some studies showed that eligible patients
had a better treatment outcome than non-eligible
patients in routine outpatient care [8]. In contrast,
we found that only exclusion of minor depression
was associated with better treatment outcome [9].
Thus, the AET exclusion criteria had a limited influ-
ence on treatment outcome.
Whereas the influence of exclusion criteria on treat-
ment outcome is a topic in research on AETs, this is
not the case for research on psychotherapy efficacy
trials (PETs). To our best knowledge, only one study
reported on the eligibility of ‘real life’ patients for
PETs. A total of 95% of patients with several common
psychiatric disorders were eligible for at least one PET
and 75% for two or more [10,11]. However, the
authors did not investigate the comparability of the ex-
clusion criteria used in the PETs. Lack of consistency
in this respect may diminish the unequivocality of the
results of PETs and thereby the generalizability of the
results to ‘real life’ patients.
In this paper, we present the effects of the most used
exclusion criteria of PETs on eligibility of ‘real life’
patients. First, we identified the exclusion criteria used
in PETs. Subsequently, we examined the proportion of
patients with unipolar depression eligible for PETs,
applying the most used exclusion criteria, to a sample
of ‘real life’ patients with major depressive disorder
(MDD) from the Leiden Routine Outcome Monitor-
ing Study [12]. Finally, we investigated the influence
of eligibility for PET on symptom outcome from the
first treatment step, in this sample.Methods
Identification of exclusion criteria in PETs
In line with previous research on the consistency in the
use of exclusion criteria in AETs [2], we performed a
search in PubMed and PsycInfo for publications in Eng-
lish on PETs for adult patients suffering from MDD.
Furthermore, we checked the reference lists of the
included publications for relevant studies. We also con-
sulted: http://www.psychotherapyrcts.org. This website is
composed by a group of researchers from the VU Uni-
versity Amsterdam, the Netherlands, and contains a
database of RCTs and comparative studies of the effect
of psychotherapy on adult depression. We selected PETs
in which outpatient treatment was investigated and in
which one of the comparison groups was treated with ei-
ther only individual cognitive behavioral therapy (CBT)
or individual interpersonal therapy (IPT) as these two
treatments are usually incorporated in treatment guide-
lines. For all the studies that met our inclusion criteria,
we retrieved eligibility criteria from their Methods
sections.
The Dutch mental health care system and treatment
steps for MDD
The Dutch mental health care system is organized in a
stepped-care-manner and uses treatment guidelines
which are based on evidence from AETs and PETs.
Patients with mood complaints visit their general practi-
tioner (GP) first. GPs will refer patients with a first epi-
sode of a mild depression either to counseling sessions
or prescribe antidepressants. The Dutch and many other
guidelines recommend that patients with moderate de-
pression should be treated with CBT or IPT or pharma-
cotherapy, based on the patient’s preferences [13-15].
Reasons to refer patients to a regional mental health
provider (RMHP) are a preference of patients for psy-
chotherapy (only provided by psychotherapists), severity
or recurrence of depression, and non-response to the
GP’s treatment. After baseline-assessment and a clinical
interview at our RMHP, patients are offered treatment
steps as recommended by the guidelines. If patients are
not too severely ill and have sufficient mastery of the
Dutch language, they are eligible for psychotherapy
when this is their preferred treatment.
Patients
Data on ‘real life’ patients were drawn from the Leiden
Routine Outcome Monitoring Study [12]. In 2002, the
RMHP Rivierduinen (service area with 1.1 million inha-
bitants), in collaboration with the University Medical
Hospital Leiden, implemented ROM and evidence-
based, stepped care protocols. In ROM, all patients re-
ferred to the RMPH for treatment of a mood, anxiety
or somatoform disorder have an extensive baseline
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three to four monthly intervals and before starting a
new treatment step. The baseline assessment com-
prises, besides a clinical interview, a standardized diag-
nostic interview (Mini-International Neuropsychiatric
Interview Plus [16], the collection of sociodemographic
and socioeconomic data, the administration of disease-
specific severity-scales, and general measures of health.
All ROM instruments are administered by independent
and specially trained research nurses. For a more ex-
tensive description of ROM, we refer to the design
paper [12]. Patients were between 18–65 years of age,
referred for treatment between January 2002 and Janu-
ary 2007 to the RMHP Rivierduinen, and had at least
one follow-up assessment.
Since the goal of this research was to evaluate the
generalizability of the results of psychotherapy trials,
which generally use symptom reduction or remission on
an observer rated instrument as primary outcome, we
used the data collected with equivalent instruments in
our ROM system. In ROM, MDD was diagnosed with
the Dutch version of the MINI-Plus and depression se-
verity was assessed with the Montgomery Asberg De-
pression Rating Scale (MADRS, [17]). To explore
putative selection bias, we performed a lost to follow up
analysis by comparison of patients only assessed at base-
line with those included in our study. We investigated
the eligibility and the effects of eligibility on outcome in
all MDD patients referred for treatment irrespective of
the treatment they received (antidepressants or psycho-
therapy). Since the type of treatment that patients receive
might influence outcome, we adjusted for ‘treatment mo-
dality’ in these analyses. To examine the effects of eligi-
bility to PETs on treatment results of psychotherapy
specifically, we also conducted the analyses in patients
who were actually treated with CBT or IPT.
Effects of exclusion criteria on symptom outcome in daily
practice
In line with previous research on exclusion criteria in
AETs [1-3,18,19], we explored the influence on outcome
of exclusion criteria used in >75% of the PETs. In line
with the methodology of PETs, we defined outcome in
our daily practice population as the extent of improve-
ment on the MADRS (difference between baseline and
post treatment), and in line with the methodology of
both AETs and PETs also as proportion of responders
(50% reduction of symptoms), and as proportion of
remitters (MADRS ≤10) [20] after the first step treat-
ment for MDD.
Statistical analysis
The effects of the exclusion criteria on outcome were
computed by univariate and multivariate linear andlogistic regression analyses. In the multivariate (adjusted)
analyses on each individual exclusion criterion, the
effects of the exclusion criterion on outcome were
adjusted for age, gender and all the other exclusion cri-
teria. In the analysis on all MDD patients we also
adjusted for ‘treatment modality’ (type of treatment that
the patients received: antidepressants, psychotherapy or
a combination of both). For the lost to follow-up ana-
lyses, independent sample t-tests and Chi-square ana-
lyses were carried out. The statistical software package
SPSS 16.0 was used.
Results
Identification of exclusion criteria in PETS
Our PubMed search yielded 3931 potentially relevant
titles of studies. Another 203 potentially relevant studies
were retrieved from reference lists of manuscripts and
from the database of the VU University Amsterdam. The
majority of these studies were carried out in specific
subgroups, such as elderly, ethnic minorities or patients
with specific somatic co morbidity (n=4085). Therefore,
these studies were excluded. Another 22 manuscripts
were excluded because they were duplicates between the
three databases. Of the remaining 27 PETs, seven were
excluded for the following reasons: in one PET the psy-
chotherapeutic intervention appeared to include a prom-
inent role for the spouse of the patients [21]; in another,
the use of in- and exclusion criteria was mentioned but
not made explicit [22] ; five PETs were excluded as they
used the same datasets as other studies already part of
our review [23] [24] [25] [26] [27]. Finally, 20 PETs
could be included [28-42]; [43-47]. In 18 studies (90%),
individual CBT was one of the intervention arms and in
5 studies (25%) individual IPT was. In 12 PETs (60%),
antidepressants (most frequently tricyclic antidepres-
sants) were used as comparison treatment. No PETs
used treatment as usual or a waiting list group as control
group.
From the PETs, we identified 38 exclusion criteria,
which we grouped into the following 15 categories (+
number of studies that reported the use of this criter-
ion): 1) bipolar disorder or a history of a (hypo-manic
episode (19 studies); 2) history of schizophrenia or
psychosis or psychotic features (18 studies); 3) current
or past abuse of or dependence on alcohol and/or drugs
(17 studies); 4) not meeting a minimum severity thresh-
old (16 studies); 5) previous use of medication or electro
convulsive therapy (ECT) (14 studies); 6) comorbid per-
sonality disorder (12 studies); 7) cognitive disorders (11
studies); 8) somatic concerns (11 studies); 9) receiving
other treatment at the start of the trial (10 studies); 10)
anxiety disorder as a primary diagnosis (9 studies); 11)
contra indication for the use of medication (9 studies);
12) suicidality (8 studies); 13) previous psychotherapy (8
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15) crisis situation (4 studies). In line with the model of
Zimmerman and colleagues on commonly used exclu-
sion criteria in AETs [2], we planned to examine the cri-
teria that were used in more than 75% of all PETs:,
which were: 1) bipolar disorder or a history of a (hypo-)
manic episode (95%); 2) schizophrenia, a history of
psychosis or psychotic features (90%); 3) current or past
abuse of or dependence on alcohol and/or drugs (85%)
and 4) not meeting a minimum severity threshold (80%;
most common: cut-off score of 14 on the Hamilton Rat-
ing Scale for Depression [48] HAM-D-17). ‘Previous use
of medication or ECT’ was used in only 70% of the
PETs, but we included this criterion in our further ana-
lyses as we hypothesized that it may have a large impact
on eligibility of ‘real life’ patients. Bipolar disorder and
psychosis are considered to be different entities from
MDD. Not only in PETs, but also in clinical practice,
patients are treated differently if they have bipolar dis-
order or a history of a (hypo-) manic episode, or a his-
tory of schizophrenia or psychosis or psychotic features.
Therefore, these exclusion criteria are not likely to
jeopardize the generalizability of the results of PETS for
MDD to daily practice. Furthermore, we included the
frequently used criteria ‘current or past abuse or depend-
ence on alcohol and/or drugs’ and ‘not meeting a mini-
mum severity threshold’ in our analyses. Comorbid
substance abuse and relatively mild depression often
occur in daily practice. Therefore, the frequently used
exclusion criteria, ‘current or past abuse or dependence
on alcohol and/or drugs’ and ‘not meeting a minimum
severity threshold’ are likely to jeopardize the
generalizability of the results of PETs to daily practice.
Since in clinical practice alcohol abuse might be more
common than drug abuse, we studied the effects of
‘current or past abuse or dependence on alcohol’ and
‘current or past abuse or dependence on drugs’ separ-
ately. Table 1, shows the exclusion criteria, the 15 sum-
marized categories and their frequencies as identified in
PETs.
Patients
Between January 2002 and January 2007, 1653 outpati-
ents seeking treatment at RMHP Rivierduinen suffered
from MDD according to the MINIplus. 774 patients
(46%) had at least one follow-up assessment. Extensive
chart-review was done for those 774 patients. As we
confined our study to patients with unipolar depression,
we excluded 42 patients who were suspected to have a
bipolar disorder or psychotic features. Furthermore, 132
patients had to be excluded from further follow-up ana-
lysis due to missing information on treatment, admission
to an inpatient-clinic during follow-up, remission on the
MADRS at baseline or a time-span between baseline andfollow-up assessment which we considered either to be
too short (less than four weeks) or too long (more than
52 weeks) to provide reliable information. Finally, 598
patients were selected for follow-up analysis. Of these
598 patients, 80 patients only received individual psy-
chotherapy (CBT or IPT) for MDD; 82 patients received
only antidepressants; 90 patients received psychotherapy
for a comorbid disorder other than MDD or the focus of
psychotherapy could not be extracted from chart review;
167 patients received a combination of psychotherapy
for MDD and antidepressants; 90 patients received anti-
depressants and social supportive counseling; 89 patients
received other forms of treatment, i.e. mood stabilizers;
group therapy, training courses. Clinical and demogra-
phical characteristics of the whole sample as well as the
80 patients who received psychotherapy only are
reported in Table 2. In an earlier study on this sample
we examined selection bias, due to loss to follow up of
patients. We showed that the patients of this sample
were very similar to the patients who were lost to follow
up [7]. In Table 2, we present the baseline features and
symptom outcome in ROM patients suffering from
MDD.
Effects of exclusion criteria on symptom outcome
As we confined our study to unipolar depression, we
excluded patients with a ‘bipolar disorder or a history of
a (hypo-) manic episode’ and patients with a ‘history of
schizophrenia or psychosis or psychotic features’ from
our daily practice sample. Hence, we did not explore the
effects of these two frequently used exclusion criteria in
PETs. We did analyze the effects of the exclusion criteria
‘current or past abuse or dependence on alcohol and/or
drugs’, ‘not meeting a minimum severity threshold’ and
‘previous use of medication or ECT’ on outcome.
In the literature, the baseline severity threshold (a cut-
off score of 14 on the HAM-D-17 for PETs) is usually
defined as a score on the HAM-D-17. In our routine clin-
ical practice (ROM), depression severity is assessed with
the MADRS. To enable comparison, we converted the
scores MADRS of the ROM patients into HAM-D-17
scores with the equation proposed by Zimmerman [49]:
MADRS = 1.43 X HAM-D + 0.87. Recently, the Item Re-
sponse Theory (IRT) was suggested to be a more reliable
method to convert MADRS scores into HRSD17 scores.
As a sensitivity analysis, we also used the IRT method [50]
procedures yielded similar results for the conversion of
the MADRS scores into HAM-D-17 scores.
Table 3 shows the proportions of patients meeting the
exclusion criteria for all 598 patients with MDD, as well
as for the 80 patients treated with psychotherapy. In the
group of all MDD patients, the criterion ‘Previous use of
medication or ECT’ had the largest effect on proportion
of eligible patients. In the 80 psychotherapy patients, the
Table 1 (Categories of) exclusion criteria found in psychotherapy efficacy trials




Bipolar disorder or history of (hypo-) manic episode 95%
Schizophrenia, a history of psychosis or psychotic features 90%
Current or past abuse or dependence on alcohol and/or drugs - Alcohol abuse or dependence 85%
- Drug abuse or dependence
Not meeting a minimum severity threshold 80%
Previous use of medication or ECT - ECT less than 6 months before start of trial 70%
- History of use of a tricyclic antidepressant
- Use of amitriptyline less than 3 months prior to trial
- Use of imipramine less than 3 months prior to trial
- Use of paroxetine less than 1 year prior to trial
- Use of any antidepressant less than 2 months prior to trial
- Use of any antidepressant less than 1 month prior to trial
- Use of any antidepressant less than 2 weeks prior to trial
- Current use of an antidepressant
Co morbid personality disorder - Borderline personality disorder 60%
- Antisocial personality disorder
- Schizotypical personality disorder
Cognitive disorders - Cognitive disorders in general 55
- Organic brain syndrome
- Delirium or dementia
- Mental retardation
Somatic concerns - Somatic co morbidity in general 55%
- Co morbid somatisation disorder




Contra indication for the use of medication in general 45%
Suicidal ideation 40%
Previous psychotherapy, with or without success History of psychotherapy
- Psychotherapy less than 5 years prior to trial
- Psychotherapy less than 2 years prior to trial
- Psychotherapy less than 1 year prior to trial
- Psychotherapy less than 2 months prior to trial
- Current psychotherapy
Psychiatric co morbidity in general, including eating disorders 25%
Crisis - Need for immediate intervention 20%
- Indication for admission
*If no subtypes are mentioned, the categorical exclusion criterion was reported in the same way in all trials.
van der Lem et al. BMC Psychiatry 2012, 12:192 Page 5 of 11
http://www.biomedcentral.com/1471-244X/12/192criterion ‘not meeting baseline severity threshold’ had
the strongest effect.
Table 4 shows the joint effects of the exclusion criteria
on symptom outcome. In the group of all 598 depressed
unipolar patients the criterion ‘current or past abuse of
or dependence on alcohol and/or drugs’ had no signifi-
cant influence. In the 80 psychotherapy patients, patientsthat met this criterion were too few in number for ana-
lysis of the effect. In the group of all 598 depressed
patients, patients with a baseline severity ≥ 14 on the
HAM-D-17 had 7.23 points (95% CI 5.31-9.14 p<0.001)
more improvement on the MADRS than patients meet-
ing the exclusion criterion of ‘not meeting minimum se-
verity threshold’. The exclusion criterion ‘not meeting a
Table 2 Baseline features and symptom outcome in ROM







Age (in years) 39.3 (SD 11.3) 36.2 (SD 10.8)
Gender (% female) 66.7% (n= 399) 73.8% (n=59)
MADRS pre treatment 25.9 (SD 6.5) 24.1 (SD 6.0)
MADRS post treatment 18.2 (SD 9.4) 16.5 (SD 9.1)
Treatment outcome
Within-Group Effectsize1 1.16 1.28
Proportion of responders2 29.1% 35.0%












Not Employed 26.1% 34.7%




Intermediate low 33.1% 23.6%
Intermediate high 38.4% 40.3%
High 16.2% 26.4%
Caption:
1 Within Group Effectsize is a definition of treatment outcome often used in
PETs and defined as: the extent of improvement (Δ MADRS pre- and post
treatment within the group under investigation) adjusted for the standard
deviation pre treatment.
2 Response is defined as a 50% reduction of symptoms on the MADRS.
3 Remission is defined as MADRS≤10.
Table 3 Exclusion criteria in ROM patients suffering from
MDD







Current or past abuse or
dependence of drugs
2.3% (n=14) 5.0% (n=4)
Current or past abuse or
dependence of alcohol
5.0% (n=30) 2.5% (n=2)
Not Meeting Baseline
Severity Threshold
21.9% (n=131) 30.8% (n=24)
Previous use of medication
or ECT
44.1% (n=230) 13.8% (n=11)
(all patients received
antidepressants, none of
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portion of responders, but decreased the proportion that
reached remission (OR 0.53, CI 0.33-0.84, p=0.01). For
the subsample of psychotherapy patients, the joint ana-
lysis of exclusion criteria showed no associations with
the exclusion criterion ‘not meeting minimum severity
threshold’.
For all 598 patients with MDD, exclusion of patients
meeting the criterion ‘previous use of medication or
ECT’ was associated with a more favourable proportion
of responders and remitters in the remaining sample
(OR 1.53, CI 1.00-2.34, p=0.05, unadjusted). Among the
80 psychotherapy patients, those who met the criterion‘previous use of medication or ECT’ had 7.2 point less
improvement on the MADRS than others (95% CI 1.94
-13.30, p<0.01, unadjusted). However, in the joint ana-
lysis with the other exclusion criteria, the associations
were no longer significant.
The explained variance (R2) of the joint influence of
the eligibility criteria respectively for all patients and
psychotherapy patients was very small (adjusted for age,
gender and type of treatment): 9 and 11% for the im-
provement on the MADRS; 2 and 7% for the proportion
of patients who responded to therapy (50% reduction of
symptoms); 4 and 7% for proportion of patients who
reached remission (MADRS ≤10).
Discussion
We evaluated the criteria for patient selection in PETs in
598 outpatients with a unipolar major depressive dis-
order in a Dutch general psychiatric outpatient setting.
We tried to follow the model developed for the
consistency of exclusion-criteria used in AETs [1,18].
However, we found a lack of consistency in the use of
exclusion criteria in PETs. Only four criteria were used
in at least 75% of the studies: ‘bipolar disorder or a his-
tory of a (hypo-) manic episode’; ‘schizophrenia, a his-
tory of psychosis or psychotic features’; ‘current or past
abuse of or dependence on alcohol and/or drugs’ and
‘not meeting a minimum severity threshold’ (most com-
mon: cut-off score 14 on the HAM-D-17). The criterion
‘previous use of medication or ECT’, was used in 70% of
the studies and would lead to exclusion of the largest
percentage (44.1%) of patients from our sample. For
patients receiving psychotherapy only, the largest per-
centage (30.8%) would be excluded because of the
criterion ‘not meeting minimum severity’. In addition,
we examined the influence of exclusion criteria for
PETs on symptom outcome in our sample. The influ-
ence of exclusion-criteria on improvement, response

















Current or past abuse or dependence on alcohol
ΔMADRS B = 2.77 B=2.09 - -
95% CI −0.85-6.39
p=0.13
95% CI: -1.50 -5.68
p=0.25












Current or past abuse or dependence on drugs
ΔMADRS B = − 0.17 B= −1.12 B=3.37 B=3.50
95% CI −5.35-5.02
p=0.95
95% CI: -6.04 -3.79
p=0.65


























Not meeting a minimum baseline severity threshold
ΔMADRS B = 6.39* B=7.23* B=3.37 B=3.50


























Previous use of medication or ECT
ΔMADRS B = 1.26 B=1.19 B=7.62* B=5.49
95%CI −0.42-2.95
p=0.14



























* = exclusion of patients who meet this criterion contributes significantly to treatment outcome.
1 Adjusted= adjusted for age, gender and treatment modality (only in all MDD patients) and for all other exclusion criteria in the model.
B= regression coefficient: amount of additional improvement on the MADRS when patients who meet this exclusion criterion are excluded.
OR= odds ratio, the chance of response or remission when patients who meet this exclusion criterion are excluded in relation to the chance of response or
remission when these patients are not excluded.
95% CI= 95% confidence interval.
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sistently used exclusion criteria are not a major threat
to the generalizability of the efficacy results found in
PETs.
Comparison of exclusion criteria used in PETs to those
used in AETs
To our knowledge there are no other studies on the
effects of the exclusion criteria used in PETs on the
generalizability to routine clinical practice. When we
compared our results to those obtained in studies on the
generalizability of AETs [2,18], there were some notable
differences. First, PETs are less consistent in the use of
exclusion criteria than AETs. The exclusion criteria ‘pre-
vious use of medication or ECT, ‘cognitive disorders’ and
‘somatic co-morbidity’ were only found in PETs. Further-
more, PETs use a lower minimum severity threshold
than AETs (14 versus 18 on the HAM-D-17) and ex-
clude cluster B personality pathology more often (57%
versus 21%). However, they less often use psychiatric co-
morbidity and suicide risk (resp. 24% versus 59% and
43% versus 75%) as exclusion criteria. Differences be-
tween PETs and AETs may have to do with the conduct
of many AETs by pharmaceutical companies, especially
for drug registration purposes. These AETs consequently
have to adhere to standard exclusion criteria formulated
by the authorities. Furthermore, pharmaceutical com-
panies may want to maximize the likelihood to find an
effect by selection of patients who are more severely ill.
They may also minimize the risk of having their drug
associated with suicide by exclusion of suicidal patients.
Although not reported in PETs, this fear may also have
led to patient exclusion in PETs.
Comparison with previous research on effects of
exclusion criteria on symptom outcome
We found that the exclusion of patients who are ‘not
meeting the baseline severity threshold of HAM-D ≤14’
is associated with a smaller proportion of patients who
reach remission (OR 0.53), while in our previous research
in the same sample we found a positive association be-
tween exclusion of patients with a baseline severity of
HAM-D≤17 (used in AETs) and probability of remission
(OR 2.0) [7]. This finding may be explained by the fact
that there were many patients in our sample who had a
baseline severity between HAM-D 14 and 17 (n= 107,
18% of our study sample) who did not reach remission
(78% of these 107 patients). We are currently investigat-
ing the characteristics of this specific group of patients
with mild depressive symptomatology who seem to be at
risk for a more chronic course of their depressive dis-
order. Furthermore, the treatment success in our sample
was rather modest, yet in line with other research done
in daily practice [51]. We commented on the differencesbetween treatment outcome in daily practice and RCTs
in previous research [52]. Interestingly, the within-group
effect size of MDD treatment in our ROM population
was relatively high compared to the modest remission
and response percentages. An explanation for this dis-
crepancy may be that we computed all symptom out-
comes for ROM reported in Table 2, including effect
sizes, on the MADRS. However, in PETs, remission and
response are often measured on the MADRS or HAM-D,
but effect sizes are usually computed on the BDI-II [53].
In our previous report, we investigated the effect sizes
for MDD treatment on the BDI-II in our ROM popula-
tion [52] and found indeed smaller effect sizes (0.85 for
individual psychotherapy) than the ones based on the
MADRS reported in the present study. Another explan-
ation is that the standard deviation on the MADRS at
baseline is relatively small in our ROM population, per-
haps as a result of the assessment by specially trained in-
dependent research nurses.
We found that patients who used medication prior to
psychotherapeutic treatment seem to benefit less from
psychotherapy. Probably, these patients are non-
responders or partial responders in a first treatment step
for MDD and may form a more treatment resistant
group. Hence, it is possible that PETs efficacy results
were increased by exclusion of these patients. However,
in routine clinical practice, many patients have used or
are on medication before they start psychotherapy.
In line with our research on the influence of exclusion
criteria of AETs on treatment outcome [7], we found an
explained variance that was very small. This suggests
that although many ‘real life’ patients are not eligible for
RCTs on MDD [1,3,6,7], the use of eligibility criteria
might not jeopardize the generalizability of the results in
‘real life’ settings. In previous research was found that
patients who were eligible for AETs had a favorable
treatment outcome [8], but the explained variance was
not explored.
Most likely many other factors, besides eligibility, con-
tribute to differences in outcome between RCTs and
daily practice, like the Hawthorne effect [54], sociode-
mographic and socio-economic differences between
RCT participants and ‘real life’ patients [9] and the ex-
tent of protocol adherence of both therapist and patient,
in which is highly invested in RCTs and likely not to the
same extent in daily practice. We elaborated more ex-
tensively on the difference between efficacy and effect-
iveness in a previous report [52]. Further research on
factors that contribute to differences in outcome be-
tween trials and daily practice is highly recommended.
Strengths
We used a large sample of patients with MDD from rou-
tine outpatient clinical practice (the Leiden Routine
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were available, enabling analysis of a subsample of
patients receiving only psychotherapy. The use of ROM
data provided comprehensive data that are very repre-
sentative and generalizable to ‘real life daily practice’
since there are nearly no restrictions for participation.
Furthermore, we consider the fact that the Dutch health-
care system provides unrestricted access to mental
healthcare as a strong quality of this research. Unre-
stricted access diminishes the possibility of selection bias
even further.
Limitations
The large variability in which exclusion criteria are
defined in PETs made loss of information unavoidable.
In addition, in our patient sample, there was a consider-
able loss to follow-up of outcome measurement. How-
ever, the study sample follow-up group was similar to
the lost-to-follow-up group for most sociodemographic
and clinical features. Patients were lost to follow-up be-
cause they dropped out of treatment or, in 38% of the
cases, remained in treatment without follow-up assess-
ments. Loss to follow up is a problem in all studies with
a more naturalistic design. For example, STAR*D
reached a loss-to-follow-up of 48% in step II of the
study [55].
In line with psychotherapy efficacy trials, we specific-
ally chose to define outcome as symptom reduction or
remission on an observer rated instrument in order to
evaluate the generalizability of results from efficacy
trials. For patients, other treatment goals might also be
important, such as improvement of social functioning or
quality of life. For therapists, other methods of defining
treatment success, might be more useful such as clinic-
ally significant change [56]. Future effectiveness re-
search, incorporating more definitions of outcome that
are relevant to patients is therefore highly recom-
mended. ROM can be a very useful methodology to sup-
port effectiveness research, and will also provide data to
improve effectiveness research itself, as it enables a com-
parison between different types of treatment in daily
practice, where one daily practice treatment can be a
control treatment for the one under investigation. It will
also provide data to explore the role of comorbid disor-
ders in treatment and to improve diagnostic procedures
in daily practice. Since there is a growing awareness that
there is not just one type of major depressive disorder,
in the future, ROM will hopefully be helpful in the step
towards personalised MDD treatment instead of “one
treatment for all”.
Another limitation of this study is the rather small
size of the patient group receiving psychotherapy only.
More patients received psychotherapy in combination
with antidepressants, which in many cases werealready prescribed by the referring physician. Unfortu-
nately, the small number of patients with documented
“current or past abuse or dependence of alcohol and/or
drugs” in our psychotherapy sample prohibited explor-
ation of this criterion. Finally, an extensive Routine
Outcome Monitoring system including diagnostic
instruments, symptom severity scales, both observer-
rated and self report, and generic instruments measur-
ing quality of life and social functioning is a costly
investment for psychiatric practice and criticism is often
heard, especially from policy makers. However, besides
the opportunities to improve the quality of treatments
in daily practice and the possibilities to scientifically
evaluate questions that rise from daily practice, it also
might be cost-effective. Since ROM provides informa-
tion on treatment progress, it might enable the clinician
to move to a next treatment step in case of stagnation
in an earlier stage. Since ROM is relatively young, re-
search in the field of its cost-effectiveness has, to our
knowledge, not been carried out yet. It is, however,
highly recommended.
Conclusions
We found that patient selection in psychotherapy trials
in MDD lacks consistency. A consistent set of exclusion
criteria is recommended in order to facilitate compari-
son between trials and especially for daily practice to
evaluate the generalizability of their results. We also
found that the most consistently used exclusion criteria
are not a major threat to the generalizability of results
found in PETs. However, PETs do somewhat improve
their results by exclusion of patients with minor depres-
sion and patients who used antidepressants prior to
psychotherapy.
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